Impact BioMedical (IBO) Q3 2024 earnings summary

Executive summary

• Impact BioMedical focuses on drug discovery and prevention, targeting neurological, oncological, and immune diseases, and is developing technologies like Linebacker, Laetose, 3F, and Equivir through licensing and partnerships.

• The company completed its IPO on September 16, 2024, raising $3.7 million net and listing on NYSE American under the ticker IBO.

• Shifted strategy from R&D to commercialization and monetization of existing technologies, with cost-cutting measures in professional and R&D expenses.

Financial highlights

• Net income for Q3 2024 was $4.2 million, compared to a net loss of $1.2 million in Q3 2023; net income for the nine months ended September 30, 2024 was $2.4 million, versus a net loss of $3.1 million year-over-year.

• Operating loss for the nine months ended September 30, 2024 was $2.5 million, improved from $2.9 million in the prior year period.

• Total assets increased to $46.7 million as of September 30, 2024, up from $44.6 million at December 31, 2023.

• Cash and cash equivalents were $2.7 million at September 30, 2024.

• Net cash used in operating activities was $2.7 million for the nine months ended September 30, 2024, compared to $2.4 million in the prior year.

Outlook and guidance

• Management plans to monetize intellectual property and tightly control operating costs to support ongoing operations.

• Focus remains on licensing and commercialization of proprietary technologies, with ongoing evaluation of new opportunities.